Company Overview
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Why Investors Should Care
Generates a return on equity of 30.7%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 27.8%.
Revenue has grown at a 48.4% CAGR over the past five years.
Trades at a P/E of 16.1, below the sector median of 25.2.
Maintains a net profit margin of 27.7%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $5.14B (+21.2% YoY); net profit $1.29B.
- Trailing 12 Months Year-on-year growth — revenue +37.7%, earnings +37.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 48.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 48.43% |
| 1 Year: | 37.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 37.70% |
Stock Price Performance
| 1 Year: | +47.64% |
| 6 Months: | +32.11% |
| 3 Months: | +23.80% |
| 1 Month: | +7.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.24 · Neutral
P/E of 16.15 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.7%.
- Healthy ROCE of 27.8%.
- Excellent profit margin of 27.7%.
- Compounding revenue at 48.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INCY Incyte Corporation SPXR3KPHARMA | 126.75 | 16.15 | $25.69B | 0.00% | 27.83% | 30.67% | 48.43% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 384.08M | 326.44M | 381.53M | 444.16M | 382.28M | 521.52M | 449.68M | 528.40M | 497.86M | 529.93M | 551.58M | 579.39M | 568.51M | 688.04M | 620.64M | 789.51M | 604.72M | 705.71M | 812.99M | 733.24M | 911.40M | 823.30M | 808.67M | 954.61M | 919.02M | 880.89M | 1.04B | 1.14B | 1.05B | 1.22B | 1.37B | 1.27B |
| Operating Income | -6.93M | -7.39M | -101.00K | - | 36.04M | 44.59M | 22.29M | - | -133.25M | 7.26M | 15.02M | - | -67.11M | 83.24M | 31.12M | - | 74.07M | 98.61M | 134.32M | - | -664.00M | 230.77M | 5.33M | - | 98.80M | 140.84M | 235.41M | 116.54M | 254.43M | 138.38M | 24.77M | 193.78M | 214.71M | 91.90M | -478.13M | 146.09M | 205.17M | 530.31M | 443.52M | 301.12M |
| Net Income | - | - | - | - | - | - | - | - | -187.08M | -12.48M | 36.05M | -149.63M | -41.14M | 52.39M | 29.18M | 69.06M | 102.31M | 105.32M | 128.27M | 111.00M | -720.64M | 290.30M | -15.20M | 149.85M | 53.53M | 149.46M | 181.74M | 37.99M | 161.43M | 112.78M | 21.70M | 203.55M | 171.27M | 169.55M | -444.60M | 106.46M | 158.20M | 405.00M | 424.17M | 303.33M |
| Diluted EPS | -0.11 | 0.05 | -0.22 | 0.29 | 0.12 | 0.18 | 0.19 | 0.05 | -0.96 | -0.06 | 0.17 | -0.71 | -0.19 | 0.24 | 0.14 | 0.32 | 0.47 | 0.48 | 0.59 | 0.51 | -3.33 | 1.32 | -0.07 | 0.68 | 0.24 | 0.67 | 0.82 | 0.17 | 0.72 | 0.50 | 0.10 | 0.90 | 0.76 | 0.75 | -2.04 | 0.54 | 0.80 | 2.04 | 2.11 | 1.47 |
| R&D Expense | 118.36M | 112.44M | 132.07M | - | 156.82M | 120.27M | 143.18M | - | 407.92M | 201.79M | 269.56M | - | 303.10M | 298.09M | 292.53M | - | 270.55M | 289.36M | 281.34M | - | 1.09B | 286.60M | 438.11M | - | 306.90M | 343.51M | 334.94M | 353.37M | 347.20M | 384.01M | 406.64M | 400.75M | 375.71M | 429.26M | 1.14B | 573.17M | 437.28M | 494.92M | 506.58M | 515.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.27M | 169.88M | 94.45M | 297.06M | 354.95M | 511.50M | 753.75M | 1.11B | 1.54B | 1.88B | 2.16B | 2.67B | 2.99B | 3.39B | 3.70B | 4.24B | 5.14B |
| Operating Income | -139.77M | 14.05M | -143.18M | 1.15M | -16.10M | -4.80M | 50.65M | 145.00M | -243.39M | 129.22M | 402.01M | -263.68M | 585.78M | 579.44M | 620.52M | 61.37M | 1.51B |
| Net Income | -211.87M | -31.85M | -186.54M | -44.32M | -83.15M | -48.48M | 6.53M | 104.22M | -313.14M | 109.49M | 446.91M | -295.70M | 948.58M | 340.66M | 597.60M | 32.62M | 1.29B |
| Diluted EPS | - | - | - | - | -0.56 | -0.29 | 0.03 | 0.54 | -1.53 | 0.51 | 2.05 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
| R&D Expense | 119.44M | 123.88M | 178.71M | 210.39M | 260.44M | 347.52M | 479.51M | 581.86M | 1.33B | 1.20B | 1.15B | 2.22B | 1.46B | 1.59B | 1.63B | 2.61B | 2.05B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 489.58M | 328.96M | 330.42M | 629.57M | 796.48M | 1.01B | 1.64B | 2.30B | 2.65B | 3.43B | 3.56B | - | 5.84B | 6.78B | 5.44B | 6.96B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.09B | 4.65B | 3.24B | 5.02B |
| Cash & Equivalents | 178.77M | 449.82M | 417.91M | 273.16M | 224.06M | 471.43M | 452.30M | 521.44M | 652.34M | 899.51M | 1.16B | 1.83B | 1.51B | - | 2.95B | 3.21B | 1.69B | 3.10B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.99M | 62.97M | 58.87M | 101.06M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 644.88M | 743.56M | 853.15M | 1.02B |
| Total Liabilities | - | - | 578.23M | 556.04M | 505.38M | 822.68M | 878.11M | 836.28M | 1.22B | 671.95M | 719.79M | 828.34M | 949.65M | - | 1.47B | 1.59B | 2.00B | 1.79B |
| Current Liabilities | - | - | 113.57M | 135.61M | 136.07M | 108.04M | 221.06M | 168.01M | 273.50M | 375.40M | 425.28M | 513.34M | 631.20M | - | 1.16B | 1.24B | 1.64B | 1.52B |
| Long Term Debt | - | - | 293.43M | 316.15M | 410.00M | 846.60M | 840.90M | 749.80M | 749.80M | 26.80M | 19.09B | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.46M | 38.29M | 43.54M | 40.41M |
| Total Equity | -220.75M | -102.38M | -88.64M | -227.08M | -174.96M | -193.11M | -81.63M | 171.16M | 419.47M | 1.63B | 1.93B | 2.60B | 2.61B | - | 4.37B | 5.19B | 3.45B | 5.17B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 222.75M | 224.29M | 193.43M | 198.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 89.41M | 304.76M | -92.99M | 336.23M | 710.66M | -124.60M | 749.49M | 969.94M | 496.49M | 335.34M | 1.41B |
| Investing Cash Flow | -105.01M | -232.49M | -349.98M | -86.42M | -87.45M | -269.00M | -207.70M | -78.54M | -207.68M | 157.52M | -102.61M |
| Financing Cash Flow | 84.74M | 44.62M | 690.21M | 14.66M | 45.71M | 71.71M | 6.18M | -794.00K | -20.03M | -2.02B | 101.04M |
| Share Buybacks | - | - | - | - | - | - | - | 0 | 0 | 2.00B | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,508.6% | 8.3% | -151.6% | 0.4% | -4.5% | -0.9% | 6.7% | 13.1% | -15.8% | 6.9% | 18.6% | -9.9% | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% |
| Net Margin % | -2,286.8% | -18.7% | -197.5% | -14.9% | -23.4% | -9.5% | 0.9% | 9.4% | -20.4% | 5.8% | 20.7% | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| ROE % | 206.9% | 35.9% | 82.1% | 25.3% | 43.1% | 59.4% | 3.8% | 24.8% | -19.2% | 5.7% | 17.2% | -11.3% | - | 7.8% | 11.5% | 0.9% | 24.9% |
| ROCE % | - | 3.7% | -74.1% | 0.6% | -3.1% | -0.8% | 6.0% | 10.6% | -12.6% | 5.8% | 13.8% | -9.0% | - | 12.4% | 11.2% | 1.6% | 27.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 15.18% | 30.76M | $3.83B |
| 2 | Blackrock Inc. | 8.90% | 18.03M | $2.24B |
| 3 | Dodge & Cox Inc. | 5.90% | 11.96M | $1.49B |
| 4 | Vanguard Capital Management LLC | 5.44% | 11.02M | $1.37B |
| 5 | State Street Corporation | 4.80% | 9.72M | $1.21B |
| 6 | Vanguard Portfolio Management LLC | 3.84% | 7.79M | $968.98M |
| 7 | AQR Capital Management, LLC | 2.63% | 5.32M | $661.76M |
| 8 | Geode Capital Management, LLC | 2.34% | 4.75M | $590.85M |
| 9 | LSV Asset Management | 2.03% | 4.12M | $512.87M |
| 10 | Invesco Ltd. | 2.01% | 4.08M | $507.49M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INCY
Incyte Corporation (INCY) Stock Analysis: Riding High On A 37.7% Revenue Growth Surge - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQMno2SzU5dW13eXhoS21uUjUwaEM4Z2hwNmo5ZmpPOHRmTEJoWnNmWlZLVTRqblVJa00yMFRHWlVQZTkzLW16bWVHU0tVRFRGcWNKcENjd3RwUGlGQ2cyVXFDVm4xMHFLTmVRc0k5d3d3Y1hMNU15M2NzTlBBekNCaEJIWUtqTnJPMGZDc3…
Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPUElVZDFVMTc4UDlBMnhvNGlxM0lheF92X1pCX0R2aE5jd3NCWXJDRldIcmNEbFd5Q0V0QXJhVXpMTG4xcVZ0bkNHWnJ4YVE1VXY1RHI4WUdPWnd3aU8wMzBCa1RvZi1FQlhWVUh5YnptUDJpc3huM3FaOGd5ZjUxUmxrQUZiMWRCaDFxMD…
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNdGluS2hJbjZOZDhpaDY0Ty03ZWk5WTlZc2RjNDljcjk5Sk5nS3BiSkp1bWZPanNLVmYxeTFtYmlaSWV1Tlp5VnB0UEJEZTNFNVZXaWFDOWx4TFNPMkRJc3JxaVdyZ2xWaFAyM2tMVXNPSXRzM1dHOG1FcUltby1OWDZ0V3dYZW1BTVVmSk…
Incyte (INCY) Stock Could Be 31% Stretched Following KRAS Data Buzz - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQcDNVQlJTX0pMblNReTl1eDFYT1pCVnpWbTBzZjZfSzk3S2c4c2Rra3NWcGZTWTNiZWZ3Ujkwc0hXX1JGdWlZMjFna2N2X2JOZWFCOHN3WnF2LTJubE5UMWZxZkRqbHJrN21YYnBfY3ZRXy03aEpQRFh4bzlrN1NfNHhVVERJSXJsVFEtej…
Incyte (INCY) Institutional Ownership 2026 $INCY - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1iZzJ4eFphMnNGZDBxZUx3enh3SXBlS3NuOTNWRE5FOFc4RzFwUDZ0WVRSQ0MwcXRncFRkZGk1bU1YcGFhd0Uwa2F4MzdDRWx6RUQ1cG9FWnZ4U29lTWlzM3pYclhuQjdZRExSV1Z5NlQ3N1o1YUxRVXFR?oc=5" target="_blank">Inc…
Incyte president Pablo Cagnoni sells $1.36m of INCY shares - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNZ0VER3hCYS1QSVV6b3JmUWtMZncwWlU3TTJGV3FBX2I2MFF6NjVpRGEtbU85LUtLVElXZ3BFeUZXdVN3UFdRUDRId3ZxbkJuejQtWmo5clV5Y1pJTlpvc0tMMVcweDFDVk03ZUJHYy1Eal9wVkN0cVdrNFp3UWM5cWlKWDB6REYzdnF4T1…
INCY — Frequently Asked Questions
What is the current share price of Incyte Corporation (INCY)?
As of 2026-09-07 16:24 PDT, Incyte Corporation (INCY) trades at $126.75 on NasdaqGS. Its 52-week range is $81.66 to $129.93.
What is the market capitalisation of INCY?
Incyte Corporation (INCY) has a market capitalisation of $25.69B on NasdaqGS.
What is the P/E ratio of INCY?
INCY trades at a trailing price-to-earnings (P/E) ratio of 16.15. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.82.
What is the return on equity (ROE) of INCY?
INCY has a return on equity (ROE) of 30.67%. Its return on capital employed (ROCE) is 27.83%.
Is INCY a good stock to buy?
This page provides a data-driven analysis of Incyte Corporation (INCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.